SYMPHOMAX
DEAD

Serial Number

85193730

Owner

KYOWA HAKKO KIRIN CO., LTD.

Attorney

Kaushal R. Odedra

Filing Date

Dec 8, 2010

Add to watchlist:

No watchlists yet
View on USPTO

SYMPHOMAX Trademark

Serial Number: 85193730

SYMPHOMAX is a trademark filed by KYOWA HAKKO KIRIN CO., LTD. on December 8, 2010. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

KYOWA HAKKO KIRIN CO., LTD. (58 trademarks)

1-6-1, OHTEMACHI, CHIYODA-KU
TOKYO , JP

Entity Type: 99

Trademark Details

Filing Date

December 8, 2010

Registration Date

Not Registered

Goods & Services

Contract manufacturing service in the field of antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of host cells; contract extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals; providing information in the field of manufacturing technology in the field of antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of manufacturing technology in the field of antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of manufacturing technology in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of manufacturing technology in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of manufacturing technology in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of manufacturing technology in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of manufacturing technology in the field of host cells; technical consultation in the field of manufacturing technology in the field of host cells; providing technical information in the field of extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals technical consultation in the field of extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals

Host cells for medical or clinical use; cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; transfected cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; pharmaceuticals, namely, central nervous system depressants, preparations for ophthalmic use, anti-histaminics, cardiotonics, arrhythmia treating agents, diuretics, hypotensors, prophylactic for the treatment of asthma, antitussives and expectorants, stomachics and digestives, antacids, hormones, namely, pituitary hormones for the treatment of infertility, thyroid hormones for the treatment of hyperthyroidism, anabolic hormones for the treatment of aplastic anemia and osteoporosis, corticosteroids for treatment of hypopituitarism, congenital adrenal hyperplasia, rheumatoid arthritis, rheumatic fever, crohn's disease, and chronic active hepatitis, estrogen and progesterone used as combined oral contraceptives, urinary antiseptics, analgesics, anti-itching agents, cataplasms for the treatment of bruises, lumbago and stiff shoulder, pharmaceutical preparations used to treat hair disorders, vitamin preparations, food enriching agents for treating vitamin deficiencies, anti-coagulants, enzyme preparations for control of malabsorption and diarrhea, anti-cancer preparations, anti-sarcoma preparations, antibiotics and their preparations for the treatment of infectious diseases, antituberculotic agents, influenza vaccines, diphtheria vaccines, tetanus vaccines, gas gangrene vaccines, Japanese encephalitis vaccines, in vitro tetrodotoxines for medical use, antiprotozoals for the treatment of trichomoniasis and dermatophytosis, anthelmintics for the treatment of threadworm and toxoplasmaosis, naturally occurring drugs for treating peptic ulcers, charred drugs for treating peptic ulcers, moxa for treating peptic ulcers, veterinary drugs for the treatment of distemper in dogs, distomatosis in dogs, coccidian in chickens, and dysentery in pigs, germination controllers and plant rearing agents, namely, herbicides, fungicides, insecticides, bactericides and rodenticides for domestic and or agricultural use, antiseptics, drugs for arteriosclerosis, oncostatic drugs for the treatment for cancer, multienzyme digestants for in vivo use; antifungal antibiotics for treating trichomoniasis and dermatophytosis, anti parkinsonism drugs, minor tranquilizers, and anti anxiety agents, medicinal preparations for the treatment of the central nervous system, the respiratory tract and the cardiovascular system, anti-bacterial preparations, monolithic preparations, medicinal preparations for the treatment of peptic ulcers, anti-inflammatory preparations, analgesic preparations, cephalosporin, cocarboxylase preparations, glutathione preparations, preparations for improving the metabolism and the peripheral circulation, plasma substitutes and extracorporeal circulation flow improvement preparations, diuretic and anti-hypertensive preparations, in vitro diagnostic reagents for medical use, in vitro extra corporeal diagnostic reagents for medical use, in vitro x-ray contrast agents for medical use, in vitro diagnostic media, pharmaceutical preparations for the treatment of insomnia and other sleep related diseases

Development of new products for others in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cells; providing technical information in the field of development of new products in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cells; technical consultation in the field of development of new products in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cells

Filing History

ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Mar 22, 2013 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Mar 22, 2013 ABN2
NON-FINAL ACTION MAILED
Aug 24, 2012 CNRT
NON-FINAL ACTION WRITTEN
Aug 24, 2012 CNRT
ASSIGNED TO EXAMINER
Aug 9, 2012 DOCK
ASSIGNED TO EXAMINER
Aug 8, 2012 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 10, 2012 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 9, 2012 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 9, 2012 TROA
NON-FINAL ACTION MAILED
Dec 27, 2011 CNRT
NON-FINAL ACTION WRITTEN
Dec 24, 2011 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 23, 2011 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 22, 2011 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Nov 22, 2011 ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Nov 22, 2011 ERSI
LETTER OF SUSPENSION MAILED
Nov 16, 2011 CNSL
SUSPENSION LETTER WRITTEN
Nov 15, 2011 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 7, 2011 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 7, 2011 CRFA
ASSIGNED TO LIE
Sep 29, 2011 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 20, 2011 TROA
NON-FINAL ACTION MAILED
Mar 21, 2011 CNRT
NON-FINAL ACTION WRITTEN
Mar 21, 2011 CNRT
ASSIGNED TO EXAMINER
Mar 12, 2011 DOCK
NOTICE OF PSEUDO MARK MAILED
Dec 14, 2010 MPMK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 13, 2010 NWOS
NEW APPLICATION ENTERED
Dec 11, 2010 NWAP